Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0773 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | MK0773 + placebo injection |
| 2 | ACTIVE_COMPARATOR | placebo to MK0773 + testosterone injection |
| 3 | PLACEBO_COMPARATOR | placebo to MK0773 + placebo injection |
| Name | Type | Description |
|---|---|---|
| MK0773 | DRUG | Three 25mg oral tablets MK0773 bid, for 12 weeks |
| Comparator: testosterone enanthate | DRUG | intramuscular injection 200mg testosterone enanthate q14d, for 12 weeks |
| Comparator: placebo oral tablet | DRUG | placebo oral tablet bid, for 12 weeks |
| Comparator: placebo injection | DRUG | placebo intramuscular injection q14d, for 12 weeks |
Inclusion Criteria: * Subject is in good general health * Subject agrees to avoid excess alcohol and strenuous physical activity during the study * Subject who is sexually active with partners of reproductive potential agrees to use two forms of appropriate contraception during the study Exclusion...
MK-0773 is an investigational small molecule being studied for sarcopenia, or loss of muscle mass, in women aged 65 years and older. It has also been evaluated in healthy postmenopausal women and healthy older men. The drug is being developed by Merck & Company, Inc. (MRK).
MK-0773 is being developed by Merck & Company, Inc., which trades under the ticker MRK. The company has conducted clinical trials of the drug in sarcopenia, osteoporosis, and healthy volunteers.
MK-0773 has completed a Phase 2 clinical trial in women with sarcopenia. It has also completed two Phase 1 trials, one in healthy postmenopausal women and one in healthy older men. The drug is investigational and not approved.
MK-0773 has been studied in three completed trials. NCT00529659 was a Phase 2 study in women with sarcopenia. NCT01011725 was a Phase 1 study in healthy postmenopausal women with osteoporosis. NCT01017458 was a Phase 1 study in healthy older men.
Yes, MK-0773 and MK0773 refer to the same drug. Clinical trial records use both spellings, with NCT00529659, NCT01011725, and NCT01017458 all studying this compound.